A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers
Latest Information Update: 30 Sep 2024
At a glance
- Drugs LY 3537031 (Primary)
- Indications Obesity; Overweight
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 30 Sep 2024 New trial record